Cannabis and Sleep Quality: A Meta-Analysis of Randomized Controlled Trials
Abstract
Pooled analysis of 14 RCTs (n=1,847) found short-term improvements in sleep onset latency with cannabinoids, but tolerance development and rebound insomnia with prolonged use. CBD showed more favorable long-term profile than THC for sleep maintenance.
Study Summary
This meta-analysis pooled data from 14 RCTs (n=1,847) examining cannabinoid effects on sleep outcomes. Studies were identified through systematic search of PubMed, EMBASE, and Cochrane Library through August 2023. Included trials used THC, CBD, or combined preparations for primary insomnia or sleep disturbance secondary to chronic pain, PTSD, or MS. Primary outcomes were sleep onset latency (SOL), total sleep time (TST), wake after sleep onset (WASO), and sleep quality ratings. Short-term cannabinoid use (≤4 weeks) significantly reduced SOL (SMD −0.47, 95% CI −0.71 to −0.23) and improved subjective sleep quality. However, studies extending beyond 4 weeks showed tolerance development and rebound insomnia upon discontinuation. CBD-dominant preparations showed more durable effects on sleep maintenance and fewer rebound effects than THC-dominant preparations. REM sleep suppression was observed with THC but not CBD.
Key Findings
- 1Short-term cannabinoids reduced sleep onset latency (SMD −0.47) across 14 RCTs
- 2Tolerance to sleep-promoting effects developed within 4 weeks of regular THC use
- 3Rebound insomnia observed upon THC discontinuation in 6 of 8 relevant studies
- 4CBD showed more durable sleep maintenance effects without significant rebound
- 5THC suppresses REM sleep; CBD does not — important for PTSD-related nightmare treatment
Clinical Implications
- Cannabinoids may be appropriate for short-term sleep aid but not chronic nightly use
- CBD is preferred over THC for long-term sleep management due to lower tolerance risk
- THC's REM suppression may benefit PTSD nightmare sufferers but impairs memory consolidation
- Intermittent rather than nightly dosing may preserve efficacy and reduce tolerance
Study Limitations
- High heterogeneity in cannabinoid products, doses, and sleep outcome measures
- Most studies had short follow-up (≤4 weeks); long-term data scarce
- Blinding integrity compromised by psychoactive effects in THC studies
- Polysomnography used in only 4 of 14 studies; most relied on subjective measures